Neuren Pharmaceuticals saw a record Q2 with DAYBUE net sales hitting US$125 million, driven by strong uptake of the new STIX formulation. The company upgraded its 2026 royalty guidance following Acadia Pharmaceuticals’ sales boost and awaits key regulatory milestones in Europe and Japan.
- Q2 2026 DAYBUE net sales rose 30% year-on-year to US$125 million
- Strong volume growth fueled by DAYBUE STIX powder formulation adoption
- European launch anticipated in early Q4 2026 pending approval
- Japan trial readout expected Sept-Nov 2026 with 2027 submission planned
- 2026 royalty guidance raised to US$53-56 million from US$50-54 million
DAYBUE Sales Hit Record Highs on STIX Adoption
Neuren Pharmaceuticals (ASX:NEU) reported a standout quarter as its partner Acadia Pharmaceuticals (Nasdaq: ACAD) posted record Q2 2026 net sales of DAYBUE® (trofinetide) at US$125 million. This marks a 30% increase from the same period last year and a 24% jump from Q1 2026, driven almost entirely by volume growth. The catalyst behind this surge is the strong market uptake of DAYBUE STIX, a new powder formulation that became broadly available in the US from April 2026.
By the end of Q2, 40% of all US DAYBUE patients had switched to the STIX formulation, with nearly half of this demand coming from new or returning patients. This early success is notable given the initial limited launch in Q1 focused on Rett syndrome Centres of Excellence. The powder format’s appeal appears to be reshaping patient access and treatment adherence in a market where personalised care options are critical.
Regulatory Progress in Europe and Japan
Neuren is also advancing its global regulatory ambitions. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion in June 2026, recommending that the European Commission grant marketing authorisation for DAYBUE to treat neurobehavioral symptoms of Rett syndrome in both adults and children aged five and older. Pending formal approval, a commercial launch in Germany is anticipated in early Q4 2026, opening a significant new market for the drug.
Meanwhile, clinical development in Japan remains on track with topline results from the ongoing trofinetide trial expected between September and November 2026. Regulatory submission in Japan is planned for 2027, potentially extending DAYBUE’s reach into another major pharmaceutical market.
Upgraded Royalty Guidance Reflects Strong Momentum
Neuren’s royalty income mirrored the sales momentum with Q2 royalties reaching US$12.9 million, a 34% rise year-on-year and 24% higher than the previous quarter. Reflecting this robust performance, Acadia increased its full-year 2026 DAYBUE net sales guidance to US$480–510 million from US$460–490 million. Correspondingly, Neuren upgraded its 2026 royalty forecast to US$53–56 million, up from US$50–54 million.
Looking further ahead, Acadia reaffirmed its target of US$700 million in DAYBUE net sales by 2028, underscoring confidence in the drug’s long-term growth trajectory. This outlook is underpinned by ongoing product innovation and expanding geographic reach.
Pipeline Progress and Strategic Positioning
Beyond DAYBUE, Neuren continues to develop NNZ-2591 (ercanetide), an investigational oral treatment for multiple neurodevelopmental disorders including Phelan-McDermid syndrome. The Phase 3 Koala trial is underway, with a 52-week open-label extension study following initial enrolment. This pipeline diversification complements Neuren’s focus on neurological conditions with high unmet need.
CEO Jon Pilcher highlighted the quarter’s achievements as “important steps toward bringing trofinetide to more patients with Rett syndrome globally,” while noting the company’s anticipation of the European launch later this year. The combination of strong sales growth, regulatory milestones, and pipeline advancement positions Neuren as a notable player in the neurological therapeutics space.
Bottom Line?
Neuren’s upgraded royalty guidance and robust DAYBUE sales set a strong foundation, but upcoming European approval and Japanese trial results will be critical inflection points.
Questions in the middle?
- Will the European Commission’s approval confirm the CHMP’s positive opinion and trigger new revenue streams?
- How will the Japanese trial results impact regulatory timelines and market entry in 2027?
- Can DAYBUE STIX sustain its early adoption momentum to drive further volume growth?